Inventor

John E. Macor

Inventor

Guilford, CT, US

Overview

1991–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 130 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds38%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations34%

A61KPreparations for medical, dental or toiletry purposes15%

C07CAcyclic or carbocyclic compounds2%

C07BGeneral methods of organic chemistry2%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%

C07KPeptides2%

C12NMicroorganisms or enzymes2%

A01KAnimal husbandry1%

G01NInvestigating or analysing materials by determining their chemical or physical properties1%

PatentTitleYear

11,053,197Carbazole derivatives2021 11,053,258Pyrimidine carboxamides as GSK-3 inhibitors2021 10,774,086GSK-3 inhibitors2020 10,752,609GSK-3 inhibitors2020 10,723,734Biaryl kinase inhibitors2020 10,676,434Carbazole derivatives2020 10,660,877Pyridyl substituted indole compounds2020 10,618,903Heteroaryl substituted aminopyridine compounds2020 10,604,504Indole carboxamide compounds2020 10,544,120Biaryl kinase inhibitors2020 10,501,451Selective NR2B antagonists2019 10,344,020Selective NR2B antagonists2019 10,329,274Indole carboxamide compounds2019 10,266,491Carbazole derivatives2019 10,253,027Aryl lactam kinase inhibitors2019 10,246,469Biaryl kinase inhibitors2019 10,202,390Heteroaryl substituted aminopyridine compounds2019 10,174,044Fused pyridines as kinase inhibitors2019 10,155,760Biaryl kinase inhibitors2018 10,071,079[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds2018 10,035,777Heterocyclic kinase inhibitors2018 9,932,320Quinoline-based kinase inhibitors2018 9,902,722'Biaryl kinase inhibitors'2018 9,809,573'Substituted pyridine derivatives useful as GSK-3 inhibitors'2017 9,737,542'Pyrrolotriazine kinase inhibitors'2017 9,738,642'Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders'2017 9,718,804'GSK-3 inhibitors'2017 9,708,337'Aryl amide-based kinase inhibitors'2017 9,688,669'Oxazolidinones as modulators of mGluR5'2017 9,221,796'Selective NR2B antagonists'2015 9,187,506'(R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders'2015 9,045,468'2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin'2015 8,969,564'Aryl ether-base kinase inhibitors'2015 8,901,305'Aryl lactam kinase inhibitors'2014 8,841,301'Selective NR2B antagonists'2014 8,748,429'CGRP receptor antagonists'2014 8,722,670'Selective NR2B antagonists'2014 8,710,061'Compounds for the reduction of Î²-amyloid production'2014 8,703,953'Aryl ether-base kinase inhibitors'2014 8,637,525'Compounds for the reduction of beta-amyloid production'2014 8,637,523'Compounds for the reduction of beta-amyloid production'2014 8,513,253'Î±-(N-sulfonamido)acetamide derivatives as Î²-amyloid inhibitors'2013 8,507,516'Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands'2013 8,497,271'Modulators of G protein-coupled receptor 88'2013 8,486,952'Compounds for the reduction of Î²-amyloid production'2013 8,481,555'Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs'2013 8,481,546'CGRP receptor antagonist'2013 8,436,000'Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity'2013 8,426,414'Modulators of G protein-coupled receptor 88'2013 8,349,880'Bicyclic compounds for the reduction of beta-amyloid production'2013 8,314,117'CGRP receptor antagonists'2012 8,309,577'Quinuclidine compounds as Î±-7 nicotinic acetylcholine receptor ligands'2012 8,304,577'Modulators of G protein-coupled receptor 88'2012 8,278,320'Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands'2012 8,026,257'Substituted heterocyclic ethers and their use in CNS disorders'2011 7,981,913'Isophthalates as beta-secretase inhibitors'2011 7,977,362'Alpha-(N-benzenesulfonamido)cycloalkyl derivatives'2011 7,902,218'Substituted tetrahydroisoquinolines as Î²-secretase inhibitors'2011 7,863,291'Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands'2011 7,842,808'Anti-migraine spirocycles'2010 7,786,122'Î±-(N-sulfonamido)acetamide derivatives as Î²-amyloid inhibitors'2010 7,772,244'Therapeutic agents for the treatment of migraine'2010 7,754,732'Spirocyclic anti-migraine compounds'2010 7,754,755'Inhibitors of 15-lipoxygenase'2010 7,745,470'Isophthalates as beta-secretase inhibitors'2010 7,601,751'Indole acetic acid acyl guanidines as Î²-secretase inhibitors'2009 7,569,578'Heterocyclic anti-migraine agents'2009 7,507,744'Spiroazabicyclic heterocyclic compounds'2009 7,408,071'N-aryl pyrrolidine derivatives as beta-secretase inhibitors'2008 7,388,007'Gamma-lactams as beta-secretase inhibitors'2008 7,384,958'Quinoline inhibitors of cGMP phosphodiesterase'2008 7,378,430'Quinoline inhibitors of cGMP phosphodiesterase'2008 7,314,883'Anti-migraine treatments'2008 7,300,936'Î±-(N-sulfonamido)acetamide derivatives as Î²-amyloid inhibitors'2007 7,244,746'Imidazolyl derivatives as corticotropin releasing factor inhibitors'2007 7,238,699'Imidazolyl derivatives as corticotropin releasing factor inhibitors'2007 7,220,862'Calcitonin gene related peptide receptor antagonists'2007 7,173,042'Quinoline inhibitors of cGMP phosphodiesterase'2007 7,125,990'Imidazolyl derivatives as corticotropin releasing factor inhibitors'2006 7,105,516'Compounds for the treatment of premature ejaculation'2006 7,067,525'Compounds useful as modulators of Melanocortin Receptors and pharmaceutical compositions comprising same'2006 7,049,314'Cyclopentyl indole derivatives'2006 6,979,691'Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same'2005 6,888,004'Imidazolyl derivatives as corticotropin releasing factor inhibitors'2005 6,852,745'Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists'2005 6,835,741'Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists'2004 6,835,737'Quinoline inhibitors of cGMP phosphodiesterase'2004 6,750,242'Positive modulators of nicotinic receptor agonists'2004 6,713,487'Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same'2004 6,706,878'Spiroazabicyclic heterocyclic compounds'2004 6,703,502'Spiroazo bicyclic heterocyclic'2004 6,642,244'Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase'2003 6,638,937'Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists'2003 6,576,644'Quinoline inhibitors of cGMP phosphodiesterase'2003 6,465,500'Indole derivatives as 5-HT1 agonists'2002 6,436,957'Indole derivatives as 5-HT1 agonists'2002 6,410,739'Indole derivatives as 5-HT1 agonists'2002 6,387,941'Indole derivatives as 5-HT1 agonists'2002 6,387,937'Indole derivatives'2002 6,380,233'Indole derivatives as 5-HT1 agonists'2002 6,369,224'Compounds'2002 6,326,379'Fused pyridine inhibitors of cGMP phosphodiesterase'2001 6,316,438'Fused pyridopyridazine inhibitors of cGMP phosphodiesterase'2001 6,255,306'4-indole derivatives as serotonin agonists and antagonists'2001 6,166,020'Aryl and heteroaryl alkoxynaphthalene derivatives'2000 6,150,388'Indole derivatives as 5-HT1 agonists'2000 6,110,914'Spiroazabicyclic heterocyclic compounds'2000 6,093,822'5-arylindole derivatives'2000 6,087,368'Quinazolinone inhibitors of cGMP phosphodiesterase'2000 6,054,464'Azabicyclic esters of carbamic acids useful in therapy'2000 5,998,429'Azabicyclic esters of carbamic acids useful in therapy'1999 5,994,352'5-arylindole derivatives'1999 5,942,524'5-arylindole derivatives'1999 5,886,008'5-arylindole derivatives'1999 5,849,739'5-arylindole derivatives'1998 5,747,501'Indole derivatives'1998 5,717,102'Indole derivatives as 5-HT1 agonists'1998 5,688,809'5-heteroarylindole derivatives'1997 5,639,779'Indole derivatives as 5-HT1-like agonists'1997 5,639,752'Indole derivatives'1997 5,607,951'Indole derivatives'1997 5,597,826'Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or antagonist'1997 5,594,014'Indole derivatives as 5-HT1 agonists'1997 5,578,612'Indole derivatives'1996 5,559,246'Indole derivatives'1996 5,559,129'Indole derivatives'1996 5,545,644'Indole derivatives'1996 5,498,626'Acylaminoindole derivatives as 5-ht1 agonists'1996 5,169,947'3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines'1992 5,051,412'Pharmaceutically active 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines'1991

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1991–2002Patents assigned to PFIZER (28)· patent assignee history

1996–2002Based in Salem, CT, US· patent location history

1997–2001Based in Penfield, NY, US· patent location history

2000–2021Patents assigned to BRISTOL MYERS SQUIBB CO (93)· patent assignee history

2000–2009Based in Flemington, NJ, US· patent location history

2002–2009Patents assigned to ASTRAZENECA AB (5)· patent assignee history

2003–2019Based in Guilford, CT, US· patent location history

2012–2015Patents assigned to MACOR JOHN E (18)· patent assignee history

2012–2015Patents assigned to OLSON RICHARD E (8)· patent assignee history

2015–2021Based in Washington Crossing, PA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
BRISTOL MYERS SQUIBB CO	93	2000–2021
PFIZER	28	1991–2002
MACOR JOHN Eself	18	2012–2015
OLSON RICHARD E	8	2012–2015
ASTRAZENECA AB	5	2002–2009

Locations

Location	Patents	Span
Guilford, CT, US	53	2003–2019
Washington Crossing, Pennsylvania, US	29	2015–2021
Flemington, New Jersey, US	12	2000–2009
Salem, CT, US	12	1996–2002
Penfield, New York, US	10	1997–2001